Molecular Pharmaceutics
Article
Notes
Delivery of Thiol to Human Fibroblast Lysosomes - Possible Role in
Supporting Lysosomal Proteolysis. J. Cell Biol. 1990, 110 (2), 327−
The authors declare no competing financial interest.
3
35. (c) Meng, F.; Hennink, W. E.; Zhong, Z. Reduction-sensitive
polymers and bioconjugates for biomedical applications. Biomaterials
2009, 30 (12), 2180−2198.
(13) Doerr, I. L.; Wempen, I.; Clarke, D. A.; Fox, J. J. Thiation of
Nucleosides. III. Oxidation of 6-Mercaptopurines1. J. Org. Chem. 1961,
ACKNOWLEDGMENTS
■
We thank Dr. Sachiko Hirosue for critical reading of the paper.
2
(
6 (9), 3401−3409.
14) Chavez-Gil, T. E.; Melen
electrochemical characterization of water soluble [(η5-C5H5)2Mo-
thionucleobase/thionucleoside)]Cl2 complexes. Inorg. Chim. Acta
004, 357 (4), 1092−1102.
15) Segura, T.; Hubbell, J. A. Synthesis and in Vitro Character-
REFERENCES
■
́
́
dez, E. Synthesis, spectroscopic and
(
1) (a) Elion, G. B. Symposium on immunosuppressive drugs.
Biochemistry and pharmacology of purine analogues. Fed. Proc. 1967,
6 (3), 898−904. (b) Elion, G. B. The Purine Path to Chemotherapy
Nobel Lecture). Angew. Chem., Int. Ed. Engl. 1989, 28 (7), 870−878.
2) (a) Ling, Y. H.; Chan, J. Y.; Beattie, K. L.; Nelson, J. A.
(
2
(
2
(
(
ization of an ABC Triblock Copolymer for siRNA Delivery.
Consequences of 6-Thioguanine Incorporation into DNA on
Polymerase, Ligase, and Endonuclease Reactions. Mol. Pharmacol.
Bioconjugate Chem. 2007, 18 (3), 736−745.
(16) Nishikawa, M.; Takakura, Y.; Hashida, M. Pharmacokinetic
1
992, 42 (5), 802−807. (b) Christie, N. T.; Drake, S.; Meyn, R. E.;
evaluation of polymeric carriers. Adv. Drug Delivery Rev. 1996, 21 (2),
35−155.
17) (a) Inomata, M.; aFukuoka, F.; Hoshi, A.; Kuretani, K.;
Nelson, J. A. 6-Thioguanine-induced DNA Damage as a Determinant
1
(
of Cytotoxicity in Cultured Chinese Hamster Ovary Cells. Cancer Res.
1
984, 44 (9), 3665−3671. (c) Parker, W. B. Enzymology of Purine
Saneyoshi, M. Antitumor activity of alkyldisulfide derivatives of 6
mercaptopurines against L-1210 leukemia. J. Pharmacobiodyn. 1981, 4
and Pyrimidine Antimetabolites Used in the Treatment of Cancer.
Chem. Rev. 2009, 109 (7), 2880−2893.
(12), 928−932. (b) Inomata, M.; Fukuoka, F.; Hoshi, A.; Kuretani, K.;
(
3) (a) Ootsu, K.; Matsumoto, T.; Aki, O.; Nakagawa, Y.; Sirakawa,
Saneyoshi, M. Structure-antitumor activity relationship of purin-6-yl
alkyl disulfides. J. Pharmacobiodyn. 1981, 4 (1), 58−64. (c) Gunnars-
dottir, S.; Elfarra, A. A. Cytotoxicity of the novel glutathione-activated
thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and
trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the
National Cancer Institute’s anticancer drug screen. Drug Metab.
Dispos. 2004, 32 (3), 321−327. (d) Gunnarsdottir, S.; Rucki, M.;
Elfarra, A. A. Novel glutathione-dependent thiopurine prodrugs:
evidence for enhanced cytotoxicity in tumor cells and for decreased
bone marrow toxicity in mice. J. Pharmacol. Exp. Ther. 2002, 301 (1),
K. Antitumor and immunosuppressive activities of alkyldithiopurine
derivatives. Gann 1972, 63 (5), 523−529. (b) Elfarra, A. A.; Duescher,
R. J.; Hwang, I. Y.; Sicuri, A. R.; Nelson, J. A. Targeting 6-thioguanine
to the kidney with S-(guanin-6-yl)-L-cysteine. J. Pharmacol. Exp. Ther.
1
(
995, 274 (3), 1298−1304.
4) Krenitsky, T. A.; Hall, W. W.; Selph, J. L.; Truax, J. F.; Vinegar, R.
Nucleosides of azathioprine and thiamiprine as antiarthritics. J. Med.
Chem. 1989, 32 (7), 1471−1475.
(
5) Kataoka, T.; Akahori, Y.; Sakurai, Y. 6-Mercaptopurine-induced
potentiation of active immunotherapy in L1210-bearing mice treated
with concanavalin A-bound leukemia cell vaccine. Cancer Res. 1984, 44
7
7−86. (e) Thomson, P.; Naylor, M. A.; Stratford, M. R. L.; Lewis, G.;
Hill, S.; Patel, K. B.; Wardman, P.; Davis, P. D. Hypoxia-driven
elimination of thiopurines from their nitrobenzyl prodrugs. Bioorg.
Med. Chem. Lett. 2007, 17 (15), 4320−4322. (f) Kirkpatrick, D. L.
Modification of Antitumor Disulfide Cytotoxicity by Glutathione
Depletion in Murine Cells. Cancer Res. 1987, 47 (16), 4391−4395.
(
2), 519−524.
(
6) (a) Tomalik-Scharte, D.; Lazar, A.; Fuhr, U.; Kirchheiner, J. The
clinical role of genetic polymorphisms in drug-metabolizing enzymes.
Pharmacogenomics J. 2008, 8 (1), 4−15. (b) Aarbakke, J.; Janka-
Schaub, G.; Elion, G. B. Thiopurine biology and pharmacology. Trends
Pharmacol. Sci. 1997, 18 (1), 3−7.
(g) Saneyoshi, M.; Inomata, M.; Sekine, T.; Hoshi, A.; Fukuoka, F.
Synthetic nucleosides and nucleotides. X. Synthesis and biological
activities of several purin-6-yl benzyl disulfides and their ribonucleo-
sides. J. Pharmacobiodyn. 1978, 1 (3), 168−174.
(
7) (a) Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh,
D.; Jarvinen, T.; Savolainen, J. Prodrugs: design and clinical
applications. Nat. Rev. Drug Discovery 2008, 7 (3), 255−270.
(18) (a) Gunnarsdottir, S.; Elfarra, A. A. Glutathione-dependent
(
b) Ringsdorf, H. Structure and properties of pharmacologically active
metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the
chemotherapeutic drug 6-mercaptopurine: evidence for two distinct
mechanisms in rats. J. Pharmacol. Exp. Ther. 1999, 290 (3), 950−957.
polymers. J. Polym. Sci.: Polym. Symp. 1975, 51 (1), 135−153.
(
8) Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor
vascular permeability and the EPR effect in macromolecular
(b) Eklund, B. I.; Gunnarsdottir, S.; Elfarra, A. A.; Mannervik, B.
therapeutics: a review. J. Controlled Release 2000, 65 (1−2), 271−284.
Human glutathione transferases catalyzing the bioactivation of
anticancer thiopurine prodrugs. Biochem. Pharmacol. 2007, 73 (11),
(
9) (a) Reddy, S. T.; van der Vlies, A. J.; Simeoni, E.; Angeli, V.;
Randolph, G. J.; O’Neil, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A.
Exploiting lymphatic transport and complement activation in nano-
particle vaccines. Nat. Biotechnol. 2007, 25 (10), 1159−1164.
1
(
829−1841.
19) Choe, Y. H.; Greenwald, R. B. Preparation of polymeric thiol-
linked prodrugs employing benzyl elimination systems.
WO2003041642A2, 2003.
(
b) Reddy, S. T.; Rehor, A.; Schmoekel, H. G.; Hubbell, J. A.;
Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with
poly(propylene sulfide) nanoparticles. J. Controlled Release 2006, 112
(
(
20) Hermanson, G. T. Bioconjugate techniques; Elsevier: 2008.
21) Kellogg, B. A.; Garrett, L.; Kovtun, Y.; Lai, K. C.; Leece, B.;
(
1), 26−34.
10) Napoli, A.; Valentini, M.; Tirelli, N.; Muller, M.; Hubbell, J. A.
Oxidation-responsive polymeric vesicles. Nat. Mater. 2004, 3 (3),
83−189.
11) (a) Cerritelli, S.; O’Neil, C. P.; Velluto, D.; Fontana, A.; Adrian,
Miller, M.; Payne, G.; Steeves, R.; Whiteman, K. R.; Widdison, W.;
Xie, H.; Singh, R.; Chari, R. V.; Lambert, J. M.; Lutz, R. J. Disulfide-
linked antibody-maytansinoid conjugates: optimization of in vivo
activity by varying the steric hindrance at carbon atoms adjacent to the
disulfide linkage. Bioconjugate Chem. 2011, 22 (4), 717−727.
(
1
(
M.; Dubochet, J.; Hubbell, J. A. Aggregation Behavior of Poly(ethylene
glycol-bl-propylene sulfide) Di- and Triblock Copolymers in Aqueous
Solution. Langmuir 2009, 25 (19), 11328−11335. (b) O’Neil, C. P.;
Suzuki, T.; Demurtas, D.; Finka, A.; Hubbell, J. A. A Novel Method for
the Encapsulation of Biomolecules into Polymersomes via Direct
Hydration. Langmuir 2009, 25 (16), 9025−9029.
(
12) (a) Lloyd, J. B. Disulphide reduction in lysosomes. The role of
cysteine. Biochem. J. 1986, 237 (1), 271−272. (b) Pisoni, R. L.; Acker,
T. L.; Lisowski, K. M.; Lemons, R. M.; Thoene, J. G.; Cysteine-Specific
Lysosomal, A Transport-System Provides a Major Route for the
2
818
dx.doi.org/10.1021/mp3001183 | Mol. Pharmaceutics 2012, 9, 2812−2818